During the past decade, Takamatsu Red Cross Hospital conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 4 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 4 clinical trials were completed. i.e. 30.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Takamatsu Red Cross Hospital" #1 sponsor was "Amgen" with 3 trials, followed by "Boehringer Ingelheim" with 2 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored, "Pfizer" with 2 trials sponsored and "ASKA Pharmaceutical Co., Ltd." with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Takamatsu Red Cross Hospital" #1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 2 trials as a collaborator and "PharmaEssentia Japan K.K." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Takamatsu Red Cross Hospital" are "Ulcerative Colitis" (4 trials), "Palmoplantar Pustulosis" (3 trials), "Crohn's Disease" (2 trials), "Actinic Keratosis" (1 trials) and "Atherosclerotic Cardiovascular Disease" (1 trials). Many other conditions were trialed in "Takamatsu Red Cross Hospital" in a lesser frequency.

Most popular intervention types in "Takamatsu Red Cross Hospital" are "Drug" (15 trials), "Other" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Etrasimod" (3 trials), "Apremilast" (2 trials), "Guselkumab" (2 trials) and "Spesolimab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Takamatsu Red Cross Hospital" are 16 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Takamatsu Red Cross Hospital". undefined are not yet recruiting, 9 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Takamatsu Red Cross Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Takamatsu Red Cross Hospital, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".